Stein: Novartis develops site into life science park
The pharmaceutical group Novartis AG is planning to develop its production site in Stein (AG) into the Rhine Valley Life Science Park. Other companies from the healthcare sector are to settle there.
Novartis has already opened up the Basel campus to startups and life science companies. The pharmaceutical company has now announced similar plans for its plant in Stein. Companies from the healthcare sector are to settle there, for which Novartis intends to provide services in the areas of building management, energy supply, engineering, maintenance, logistics as well as wastewater treatment and waste disposal. A local site development team is in place for this purpose, which has already implemented the settlement of two companies, according to the company.
The site currently employs more than 2,000 people from three pharmaceutical and biotechnology companies in research, development and production. Novartis says it operates one production plant each in Stein for solid dosage forms, drugs for injection and for cell and gene therapies, as well as a grinding and mixing centre for chemical production. In addition to Novartis, the chemical and pharmaceutical group Lonza has been present in Stein since 2019, and the biotechnology company Celonic since the beginning of 2021.
Novartis had invested more than CHF 200 million at the Stein and Schweizerhalle sites in 2020 and 2021. According to the company, the Stein site is home to two of its largest production plants: the Solids plant and the Steriles plant. (tp)
